The Efficacy of Neuromodulation Interventions for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Runbing Xu,Changhe Yu,Xinyu Zhang,Yipin Zhang,Mengfei Li,Bei Jia,Shiyan Yan,Miao Jiang
DOI: https://doi.org/10.2147/jpr.s448528
IF: 2.8319
2024-04-12
Journal of Pain Research
Abstract:Runbing Xu, 1, &ast Changhe Yu, 2, &ast Xinyu Zhang, 1 Yipin Zhang, 1 Mengfei Li, 1 Bei Jia, 1 Shiyan Yan, 3 Miao Jiang 1, 4 1 Hematology and Oncology Department, Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing, People's Republic of China; 2 Tuina and Pain Management Department, Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing, People's Republic of China; 3 School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 4 School of Life Science, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Miao Jiang, School of Life Science, Beijing University of Chinese Medicine, Gongchen Street, Beijing, People's Republic of China, Tel +8613511072205, Email Shiyan Yan, School of Acupuncture-Moxibustion and Tuina, Gongchen Street, Beijing University of Chinese Medicine, Beijing, People's Republic of China, Tel +8613521436209, Email Purpose: To determine the efficacy and safety of a neuromodulation intervention regimen in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Patients and Methods: Systematic searches were conducted in seven English databases. Randomized controlled trials of all neuromodulation interventions (both invasive and non-invasive) for the treatment of CIPN were selected. Group comparisons of differences between interventions and controls were also made. We divided the outcomes into immediate-term effect (≤ 3 weeks), short-term effect (3 weeks to ≤ 3 months), and long-term effect (> 3 months). Results: Sixteen studies and 946 patients with CIPN were included. Among immediate-term effects, neuromodulation interventions were superior to usual care for improving pain (SMD=− 0.77, 95% CI − 1.07~ 0.47), FACT-Ntx (MD = 5.35, 95% CI 2.84~ 7.87), and QOL (SMD = 0.44, 95% CI 0.09~ 0.79) (moderate certainty); neuromodulation loaded with usual care was superior to usual care for improving pain (SMD=− 0.47, 95% CI − 0.71 ~ − 0.23), and QOL (SMD = 0.40, 95% CI 0.12 ~ 0.69) (moderate certainty). There were no statistically significant differences between the neuromodulation interventions regimen vs usual care in short- and long-term outcomes and neuromodulation vs sham stimulation from any outcome measure. There were mild adverse events such as pain at the site of stimulation and bruising, and no serious adverse events were reported. Conclusion: Neuromodulation interventions had significant immediate-term efficacy in CIPN but had not been shown to be superior to sham stimulation; short-term and long-term efficacy could not be determined because there were too few original RCTs. Moreover, there are no serious adverse effects of this therapy. Keywords: chemotherapy, peripheral neuropathy, neuromodulation, systematic review, meta-analysis Chemotherapy-induced peripheral neuropathy (CIPN) is the most common dose-limiting side effect during cancer therapy. Various conventional cytotoxic drugs can cause CIPN, such as paclitaxel, platinum, periwinkle alkaloids, proteasome inhibitors, thalidomide and so on. 1,2 The symptoms of CIPN commonly occur in the hands and feet, while the symptoms are more severe in the lower extremities than the upper extremities. The typical clinical features include tingling, numbness, burning, symmetrical "socking type", and other paresthesias and dysesthesias. 3,4 Meanwhile, some patients may experience ataxia and other motor symptoms. 5,6 CIPN seriously affects the quality of life for cancer patients, and symptoms may continue for extended periods. The treatment's efficacy may be compromised if the chemotherapy dose is lowered or stopped too soon due to a severe adverse effect. 7,8 The conventional CIPN treatments are pharmacological interventions and non-pharmacological interventions. 4,9 According to the American Society of Clinical Oncology and the European Society for Medical Oncology guidelines, duloxetine is recommended for CIPN pain management with moderate evidence. 2–4 However, a recent meta-analysis shows that duloxetine's efficacy in treating CIPN is not considerably more remarkable than the placebo effect, and caution should be used concerning its side effects. 10,11 Based on the above discussion, the search for a proven treatment is critical. Non-pharmacological interventions for CIPN have become a research hotspot. Neuromodulation interventions, as a rapidly evolving multidisciplinary non-pharmacological therapy, are now wide -Abstract Truncated-
clinical neurology